ESMO 2025: Bladder cancer highlights

ESMO 2025: Prostate highlights

ESMO 2025: Renal highlights

Durvalumab with BCG and maintenance therapy improves disease-free survival in high-risk NMIBC

Perioperative enfortumab vedotin plus pembro improves survival and pCR in cisplatin-ineligible MIBC

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2+ early breast cancer

Tarlatamab shows manageable safety profile with fewer toxicities than chemo in 2L SCLC

Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient

WCLC 2025: Latest in EGFR positive NSCLC

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results

Key insights from lung cancer research at ASCO 2025